MP0250 + bortezomib + dexamethasone

MP0250 + bortezomib + dexamethasone is a combination therapy under investigation for the treatment of multiple myeloma, particularly in patients who are refractory to proteasome inhibitors and/or immunomodulatory drugs. MP0250 is a first-in-class, tri-specific multi-DARPin® (Designed Ankyrin Repeat Protein) biologic that simultaneously neutralizes vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor (HGF), while also binding human serum albumin to extend plasma half-life. By inhibiting both VEGF-A/VEGFR and HGF/c-MET pathways—key drivers of angiogenesis, tumor growth, metastasis, and drug resistance in multiple myeloma—MP0250 disrupts the tumor microenvironment and enhances responses to standard therapies such as bortezomib (a proteasome inhibitor) and dexamethasone (a corticosteroid). The combination aims to overcome resistance mechanisms by targeting both angiogenic signaling and stromal support within the bone marrow[1][4][5][7].